Citius Pharmaceuticals Total Assets 2011-2025 | CTXR

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Citius Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
117 M	104 M	114 M	142 M	43.8 M	29 M	31.1 M	24.4 M	22 M	742 K	1.56 M	-	135	212

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
142 M	135	48.4 M

Quarterly Total Assets Citius Pharmaceuticals

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
128 M	121 M	121 M	117 M	97.1 M	90.7 M	97.4 M	104 M	110 M	104 M	112 M	114 M	120 M	128 M	138 M	142 M	147 M	142 M	35.3 M	43.8 M	43.8 M	43.8 M	25 M	36.7 M	29 M	29 M	28.1 M	31.1 M	31.1 M	31.1 M	28.5 M	24.4 M	24.4 M	24.4 M	21.5 M	22 M	22 M	22 M	347 K	742 K	742 K	742 K	823 K	1.56 M	1.56 M	1.56 M	108 K	-	-	5.95 K	99	135	135	135	216	212	212	212

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
147 M	99	48.9 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Amphastar Pharmaceuticals AMPH	1.58 B	$ 25.27	-2.43 %	$ 1.22 B	USA
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	144 M	$ 4.75	1.61 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	220 M	$ 3.26	-3.12 %	$ 252 M	USA
AlloVir ALVR	119 M	-	4.14 %	$ 49.1 M	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	283 M	-	-15.15 %	$ 60.3 M	Britain
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Aeglea BioTherapeutics AGLE	608 M	-	-	$ 1.01 B	USA
Kamada Ltd. KMDA	372 M	$ 7.03	0.14 %	$ 260 M	Israel
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Ascendis Pharma A/S ASND	1.18 B	$ 220.27	4.81 %	$ 5 B	Danmark
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Enlivex Therapeutics Ltd. ENLV	27.7 M	$ 0.91	-5.01 %	$ 18.7 M	Israel
Can-Fite BioPharma Ltd. CANF	9.12 M	$ 0.28	-2.28 %	$ 609 M	Israel
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.3	-3.51 %	$ 7.94 B	Australia
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
AstraZeneca PLC AZN	104 B	$ 89.78	-0.57 %	$ 96.9 B	Britain
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
Anika Therapeutics ANIK	271 M	$ 9.57	0.84 %	$ 140 M	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	5.92 B	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	23.8 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	226 M	-	-7.31 %	$ 87 M	USA
Benitec Biopharma BNTC	99.6 M	$ 12.05	-7.06 %	$ 496 M	USA
Aytu BioScience AYTU	124 M	$ 2.34	2.59 %	$ 14.7 M	USA
Nymox Pharmaceutical Corporation NYMX	654 K	-	-19.68 %	$ 18.4 M	Canada
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Aptorum Group Limited APM	16.1 M	$ 1.29	-3.01 %	$ 7.03 M	China
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Baudax Bio BXRX	10 M	-	0.59 %	$ 63 K	USA
Avenue Therapeutics ATXI	2.67 M	-	-52.27 %	$ 4.45 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Catalyst Biosciences CBIO	117 M	$ 14.01	-8.49 %	$ 922 M	USA
ChromaDex Corporation CDXC	68.3 M	-	-0.88 %	$ 598 M	USA
Axon Enterprise AXON	4.47 B	$ 566.18	-2.56 %	$ 42.9 B	USA
Cerus Corporation CERS	201 M	$ 2.16	0.47 %	$ 399 M	USA
Checkpoint Therapeutics CKPT	7.47 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	35 M	-	-16.75 %	$ 25.8 M	USA
Clovis Oncology CLVS	473 M	-	-7.23 %	$ 13 M	USA
Biogen BIIB	28 B	$ 174.42	1.11 %	$ 25.4 B	USA
BioVie BIVI	21.6 M	$ 1.42	-5.96 %	$ 2.1 M	USA
Celldex Therapeutics CLDX	792 M	$ 27.36	-2.09 %	$ 1.76 M	USA
Cortexyme CRTX	168 M	-	-1.05 %	$ 67.1 M	USA
Cellectar Biosciences CLRB	12.1 M	$ 3.63	-3.97 %	$ 44.4 M	USA
Deciphera Pharmaceuticals DCPH	474 M	-	-	$ 2.18 B	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	1.08 B	$ 11.54	0.87 %	$ 746 M	USA